EQ
EQRx
Cambridge MAFounded 2019150 employees
Private CapbiotechPrivateOncologyImmunology
Platform: Value Pricing
Market Cap
N/A
All Drugs
4
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Sovalucimab | EQR-3096 | NDA/BLA | 1 | TROP-2 | CholangiocarcinomaDravet | ||
| Elratenlimab | EQR-8384 | Phase 3 | 1 | CDK2 | PNHPAH | ||
| Lisozumab | EQR-4256 | NDA/BLA | 2 | JAK2 | RBLN | ||
| EQR-8061 | EQR-8061 | Phase 1 | 1 | BCL-2 | MCCAML |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)